A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A

doi:10.1182/blood.2020009984

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Identifier:nobleid.org/w1/20260526/90DF8DCF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/90DF8DCF.svg?ark=w1%2F20260526%2F90DF8DCF)](https://nobleid.org/work/w1/20260526/90DF8DCF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Identifier:nobleid.org/w1/20260526/90DF8DCF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/90DF8DCF.svg?ark=w1%2F20260526%2F90DF8DCF)](https://nobleid.org/work/w1/20260526/90DF8DCF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work